Liquid Biopsy-Guided Therapy Switching Market is estimated to be valued at USD 1.24 Bn in 2026 and is expected to reach USD 2.40 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.9% from 2026 to 2033.
| Report Coverage |
Report Details |
| Base Year: |
2025 |
Market Size in 2026: |
USD 1.24 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: |
9.90% |
2033 Value Projection: |
USD 2.40 Bn |
Liquid biopsy guided therapy switching is a new precision oncology strategy based on circulating tumor DNA (ctDNA), circulating tumor cells and other biomarkers in blood and body fluids to monitor tumor changes and guide therapy switching. Unlike conventional tissue biopsies, it enables minimally invasive, repeated assessment of emerging resistance mutations, disease progression, and treatment response.
Specific therapies and immunotherapies are creating the need for timely biomarker-based treatment decisions, and the market is gaining momentum. Advances in next-generation sequencing, digital PCR and bioinformatics are helping improve mutation detection and molecular monitoring, allowing more tailored approaches to cancer treatment and enabling clinicians to adjust therapies as cancers evolve.
Market Dynamics
The global liquid biopsy-guided therapy switching market is driven by the growing incidence of cancer, increasing demand for customized oncology, and technological advancements in next-generation sequencing (NGS), digital PCR, and circulating tumor DNA (ctDNA) analysis. Regulatory approvals of liquid biopsy companion diagnostics and increasing clinical evidence of mutation-guided treatment changes further encourage the adoption in oncology centers and diagnostic laboratories.
However, a number of constraints are present in the market, such as high testing costs, inconsistent reimbursement and variability in testing protocols and differences in regulatory requirements across countries. Nevertheless, significant opportunities exist within the AI-driven analysis of multi-omic data, improved detection of emerging treatment resistance, and expansion of liquid biopsy applications across additional cancer types, enabling more precise and adaptive treatment decisions.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global liquid biopsy-guided therapy switching market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Guardant Health, Inc., F. Hoffmann-La Roche Ltd., Foundation Medicine, Inc., Labcorp Holdings Inc., Tempus AI, Inc., Caris Life Sciences, Inc., NeoGenomics Laboratories, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., and Exact Sciences Corporation
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global liquid biopsy-guided therapy switching market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global liquid biopsy-guided therapy switching market
Market Segmentation
- Biomarker Type Insights (Revenue, USD Bn, 2021 - 2033)
- ESR1 Mutations
- EGFR Mutations
- KRAS Mutations
- Other Actionable Biomarkers
- Liquid Biopsy Technology Insights (Revenue, USD Bn, 2021 - 2033)
- Next-Generation Sequencing (NGS)
- Digital PCR (dPCR/ddPCR)
- PCR-Based Assays
- Cancer Type Insights (Revenue, USD Bn, 2021 - 2033)
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Others
- Therapy Switching Approach Insights (Revenue, USD Bn, 2021 - 2033)
- Switching Treatment Before Clinical Progression Based on Molecular Resistance
- Switching Treatment at Clinical or Radiographic Progression
- Switching Treatment Based on Molecular Response or Emerging Biomarkers
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals and Oncology Centers
- Diagnostic and Reference Laboratories
- Pharmaceutical and Biotechnology Companies
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Guardant Health, Inc.
- F. Hoffmann-La Roche Ltd.
- Foundation Medicine, Inc.
- Labcorp Holdings Inc.
- Tempus AI, Inc.
- Caris Life Sciences, Inc.
- NeoGenomics Laboratories, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Exact Sciences Corporation